- Home
- BRAG vs ANL Comparison
BRAG vs ANL Comparison
Compare BRAG & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRAG
- ANL
- Stock Information
- Founded
- BRAG 2018
- ANL 2004
- Country
- BRAG Canada
- ANL Cayman Islands
- Employees
- BRAG N/A
- ANL N/A
- Industry
- BRAG Office Equipment/Supplies/Services
- ANL
- Sector
- BRAG Technology
- ANL
- Exchange
- BRAG Nasdaq
- ANL Nasdaq
- Market Cap
- BRAG 74.8M
- ANL 61.8M
- IPO Year
- BRAG N/A
- ANL 2023
- Fundamental
- Price
- BRAG $2.89
- ANL $1.70
- Analyst Decision
- BRAG Buy
- ANL Hold
- Analyst Count
- BRAG 4
- ANL 1
- Target Price
- BRAG $7.00
- ANL N/A
- AVG Volume (30 Days)
- BRAG 62.4K
- ANL 10.9K
- Earning Date
- BRAG 11-13-2025
- ANL 10-21-2025
- Dividend Yield
- BRAG N/A
- ANL N/A
- EPS Growth
- BRAG N/A
- ANL N/A
- EPS
- BRAG N/A
- ANL N/A
- Revenue
- BRAG $123,209,630.00
- ANL N/A
- Revenue This Year
- BRAG $6.62
- ANL N/A
- Revenue Next Year
- BRAG $5.85
- ANL N/A
- P/E Ratio
- BRAG N/A
- ANL N/A
- Revenue Growth
- BRAG 10.90
- ANL N/A
- 52 Week Low
- BRAG $2.59
- ANL $1.10
- 52 Week High
- BRAG $6.12
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- BRAG 48.52
- ANL 45.66
- Support Level
- BRAG $2.80
- ANL $1.70
- Resistance Level
- BRAG $2.95
- ANL $1.80
- Average True Range (ATR)
- BRAG 0.15
- ANL 0.09
- MACD
- BRAG 0.03
- ANL -0.01
- Stochastic Oscillator
- BRAG 45.61
- ANL 31.77
About BRAG Bragg Gaming Group Inc.
Bragg Gaming Group Inc is predominantly a B2B online gaming technology platform and casino content aggregator. The Company's proprietary studios offer high-performing, data-driven casino gaming titles from in-house brands Wild Streak, Spin, Atomic Slot Lab, Indigo Magic, and Oryx Gaming. It offers a full range of games including slot games, table games, card games, video bingo, scratch card games, virtual sports, and live dealer games which are featured on the company's PAM platform and also available for use on other gaming platforms offered by third parties. Geographically, the company generates a majority of its revenue from the Netherlands and the rest from Curacao, Malta, the United States, Croatia, and other regions.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.